Fora Capital, LLC Arcus Biosciences, Inc. Transaction History

Fora Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $131,256 - $183,652	-4,874 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $65,178 - $102,481	2,865 Added 142.61%	4,874 $134 Million
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $66,158 - $104,675	-2,529 Reduced 55.73%	2,009 $56 Million
Q4 2020 Feb 12, 2021	BUY	$17.0 - $32.36 $77,146 - $146,849	4,538 New	4,538 $117,000
Q3 2020 Nov 13, 2020	SELL	$17.14 - $25.47 $92,693 - $137,741	-5,408 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $75,549 - $197,716	5,408 New	5,408 $134 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Fora Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Fora Capital, LLC with notifications on news.